Mosliciguat PHocus study succeeds, and other pharma news
PHocus study succeeds The PHocus study, a Phase 2 trial evaluating the safety and effectiveness of the new drug mosliciguat for pulmonary hypertension associated with interstitial lung disease. (PH-ILD), reported good results. After 16 weeks of taking mosliciguat, participants’ pulmonary vascular resistance dropped by over half, their six-minute walk distance increased by 35m, and their NTproBNP level also dropped by half. Based on these very encouraging results, Pulmovant be
What do blood clots have to do with pulmonary hypertension?
October 13 is World Thrombosis Day A thrombosis is a blood clot inside a blood vessel, and October 13 is World Thrombosis Day, a global campaign to raise awareness of blood clots and their risk factors. This year’s campaign highlights women’s blood clot risks throughout life, including those associated with hormonal changes, pregnancy, and menopause. Blood clots can have serious consequences, including pulmonary embolism, which occurs when a clot blocks blood flow in the lung
Real voices, real change: listening to lived experience with mental health
October 10 is World Mental Health Day When we talk about pulmonary hypertension (PH), we often focus on symptoms, medications, side effects, and medical appointments, but taking care of yourself when you have PH means looking after more than your physical symptoms. Your mental health matters, too. Acknowledging the emotional impact of PH tells a more complete story. Talking openly about mental health helps normalize the emotional challenges that can come with a chronic illnes
.jpg)
